Evonik Industries has shown significant growth, with a 25% EBITDA increase and a 42% FCF rise, making it a strong investment. The company's reorganization and focus on renewables position it well for future growth, despite current macroeconomic volatility. My price target for Evonik is €24.5/share, with a "Buy" rating due to its undervaluation and potential for long-term gains.
Evonik Industries AG (OTCPK:EVKIF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Christian Kullmann - Chairman of the Executive Board Maike Schuh - Chief Financial Officer Conference Call Participants Andreas Heine - Stifel Chetan Udeshi - JPMorgan Sebastian Bray - Berenberg Martin Roediger - Kepler Cheuvreux Georgina Iwamoto - Goldman Sachs Christian Kullmann Thanks a lot, and welcome, ladies and gentlemen, to our full-year earnings call. We have four key messages that we want to bring across today.
Evonik's restructuring into growth and efficiency segments, with a focus on premiumization and defensive markets, has shown mixed results amid challenging industrial macro conditions. Despite a stable 3Q24 with improved EBITDA and cost savings, the company's forecasted growth has not fully materialized, leading to a conservative "Buy" rating. The company's high dividend yield, conservative credit rating, and potential for earnings reversal present an attractive investment opportunity, despite current volatility and ownership pressure.
Evonik Industries AG (OTCPK:EVKIF) Q3 2024 Earnings Conference Call November 6, 2024 5:00 AM ET Company Participants Christian Kullmann - Chief Executive Officer Maike Schuh - Chief Financial Officer Tim Lange - Head, Investor Relations Conference Call Participants Thomas Wrigglesworth - Morgan Stanley Chetan Udeshi - JPMorgan Andreas Heine - Stifel Sebastian Bray - Berenberg Martin Roediger - Kepler Cheuvreux Jaideep Pandya - On Field Research Operator Ladies and gentlemen, welcome to the Evonik Industries Q3 2024 Earnings Conference Call. I'm Vicky, the chorus call operator.
Evonik has shown growth and strong performance in 3Q and 4Q23, with a 19% increase in share price since the last article. The company is undergoing a strategic realignment and investing in future technologies, leading to long-term growth opportunities. Evonik remains undervalued, with a positive outlook for 2024E and potential for 15%+ annualized upside, making it a "BUY".